Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

novartis_side_building

Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

October 10, 2019 Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …
News
lung_ambition_alliance

The Lung Ambition Alliance: Stronger together

October 9, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, lung cancer, pharma

Following our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …
Feature

FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture

October 9, 2019 Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma

The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …
News
gsk_l_rgb

GSK partners with Lyell Immunopharma to develop cell therapies for cancer

October 9, 2019 Research and Development

GlaxoSmithKline and Lyell Immunopharma have announced a five-year agreement to jointly develop new technologies to improve cell therapies for the …
News
novartis_window

Novartis’ ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

October 9, 2019 Research and Development Novartis, legelizumab, pharma, urticaria

Novartis has pulled back the curtain on new Phase 2b data for its IgE/FceR1 pathway-blocking drug ligelizumab, showing that the …
News
jj_sign_on_wall

Johnson & Johnson ordered to pay man $8bn over breast growth

October 9, 2019 Research and Development

US pharma giant Johnson & Johnson has been ordered to pay $8 billion in punitive damages to a man over …
News

FDA approves Clinuvel’s Scenesse for rare genetic disorder

October 9, 2019 Research and Development

The US FDA has approved Clinuvel’s Scenesse (afamelanotide 16mg) as the first ever treatment for a rare genetic metabolic disorder …
News
merdad_parsey

Gilead appoints Merdad Parsey as Chief Medical Officer

October 7, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Gilead Sciences have announced that Merdad Parsey will join the company as Chief Medical Officer, effective November 1st. Dr Parsey …
Appointment

Breaking through limits in lung cancer: Introducing the Lung Ambition Alliance

October 7, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, feature, lung cancer, pharma

Lung cancer kills more patients than any other variety of cancer, accounting for around a fifth of all cancer-related deaths …
Feature
7359dba7-e1da-4eb4-8765-58da6178899b

Sarepta’s investigational gene therapy shows strength in limb-girdle muscular dystrophy Type 2E

October 7, 2019 Research and Development, Sales and Marketing muscular dystrophy, pharma, sarepta

Sarepta Therapeutics has revealed positive new data for its investigational gene therapy SRP-9003 in the treatment of limb-girdle muscular dystrophy …
News
jj_sign_on_wall

Johnson & Johnson commits $500m to end HIV and TB Epidemics

October 4, 2019 Medical Communications, Research and Development

Johnson & Johnson have announced it has committed to ensuring more than $500 million is dedicated to R&D delivery programs …
News
shutterstock_212432119

Arbutus Biopharma moves to terminate development of chronic hepatitis B therapy after trial failure

October 4, 2019 Medical Communications, Research and Development Arbutus Biopharma, hepatitis B, pharma

Arbutus Biopharma has announced its decision to terminate the development of its oral capsid inhibitor, known as AB-506, in the …
News
novartis_side_building

Novartis selects Microsoft for AI drug development

October 3, 2019 Research and Development

Novartis has begun an alliance with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and …
News

Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis

October 3, 2019 Research and Development

Novartis has announced positive data from its PREVENT trial, which evaluated the safety and efficacy of Cosentyx (secukinumab) for patients …
News
sandrock-al-e1548286908776

Biogen announces leadership updates

October 2, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Biogen have announced updates to it senior leadership team with Alfred Sandrock being named Executive Vice President of Research and …
Appointment
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026